Loading...
Loading...
VXRT| Name | Value |
|---|---|
| Revenues | 6.4M |
| Cost of Revenue | 1.1M |
| Gross Profit | 5.3M |
| Operating Expense | 21.6M |
| Operating I/L | -16.3M |
| Other Income/Expense | -0.2M |
| Interest Income | 0.4M |
| Pretax | -16.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -16.5M |
Vaxart, Inc. is a clinical-stage biotechnology company specializing in the development of oral recombinant protein vaccines. The company's product pipeline includes oral tablet vaccines for norovirus, seasonal influenza, respiratory syncytial virus, and coronavirus. Vaxart is also working on therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company generates revenue through the development and commercialization of its oral vaccine platform, targeting various infectious diseases and cancers.
